Cosa c'è di nuovo per trattare l'anemia Milano 20 Aprile 2016


Patogenesi delle Anemie Sideropeniche

M. Domenica Cappellini

Fondazione IRCCS Ca Granda Policlinico

Università degli Milano








- Member of advisory board for:
 - Novartis
 - Sanofi Genzyme
 - Celgene




- ✓ Global burden of anemia
- Definition Iron Deficiency (ID) and Iron
 Deficiency Anemia (IDA)
- ✓ Iron Metabolisim
- ✓ Causes of ID/IDA

The global burden of anaemia

- 32.9% global anaemia prevalence
- 68.4 mio years lived with disability (YLD, anaemia)
 - i.e. 8.8% of total for all conditions




Prevalence of anaemia by aetiology



Kassebaum NJ, et al. Blood 2014;123:615-24


ID and ID(A): Definition



Iron Deficiency Anaemia

- Depleted iron stores
- Haemoglobin (Hb) concentration falls below defined lower limit (12g/dl for women, 13 g/dl for men)


ID and ID(A): Relationship with anaemia



Schematic representation only. Areas do not reflect the real magnitude of the problem.

World Health Organization. Iron deficiency anaemia. Assessment, prevention and control: A guide for programme managers.; 2001:1-114.

ID and ID(A): Causes




1. Zimmerman MB, et al. *Lancet* 2007;370:511-20.; 2. Roux H, et al. *Eat Weight Disord*. 2013;18(2):175-82.; 3. Aapro M, et al. *Ann Oncol* 2012;23:1954-62.; 4. Marret H, et al. *Eur J Obst Gyn Reprod Biol* 2010;152:133-7.; 5. Milman N. *Ann Hematol* 2006;85:559-65.; 6. Crichton R. UNI-MED Verlag AG, 2008.; 7. Stein J, et al. *Nat Rev Gastroenterol Hepatol* 2010;7:599-610.



- ✓ Global burden of anemia
- Definition Iron Deficiency (ID) and Iron
 Deficiency Anemia (IDA)
- ✓ Iron Metabolism
- ✓ Causes of ID/IDA

Physiological iron turn-over




Adapted from Andrews N. N Engl J Med 1999;341:1986–1995

The iron cycle

Iron absorption

Enterocyte


- 1–2 mg/day
- Hepcidin-regulated
- Balanced by iron losses (1–2 mg/day)
- Reduced in inflammation
- Increased in iron deficiency



CP = ceruloplasmin; DCYTB = duodenal cytochrome B; DMT1 = divalent metal transporter 1; FPN = ferroportin.


Iron recycling Macrophage

- 20–30 mg/day
- Hepcidin-regulated
- Balanced by erythroid request
- Reduced in inflammation
- Increased in iron deficiency




Finch C. Blood. 1994;84:1697-702. Andrews NC. Blood. 2008;112:219-30.

Hepcidin: The master regulator of iron homeostasis



Hepcidin is the master regulator of systemic iron homeostasis


 The liver peptide hepcidin regulates intestinal iron absorption and iron release from storage cells by binding ferroportin, causing its internalization and degradation, and thus exerting a general inhibitory effect on iron release in the body



FPN = ferroportin.

Nemeth E, et al. Science. 2004;306:2090-3.


Hepcidin upregulation: two pathways




LPS = lipopolysaccharide.

* Indicates proteins whose inactivation causes iron overload.


Hepcidin downregulation: multiple pathways




Hepcidin regulation by anaemia




Erythroferrone (ERFE) the newly identified erythroid regulator Proposed mechanism of action




'Traditional' view of iron – a critical element in oxygen delivery (erythropoiesis)



MCV During Differentiation




Globins, iron, and heme play a critical role in MCV determination



Mean MCV 0 day 131 fL 7 day 99 fL 14 day 86 fL

Data obtained from erythroid cultures (Drs. Iolascon and De Falco). Graphics courtesy of Prof. Achille Iolascon.




Characteristics of Microcytosis

RBC: Microcytosis hypochromia reduced size and reduced Hb content of red blood cells, as inferred by erythrocyte indexes

Age	MCV (fl)			
At born	110-128			
5-24 months	80-85			
2-6 years	75-90			
6-12 years	78-95			
>12 years	80-100			

Normal values for age

MCH: <26 pg (n.v 27-30) MCHC: <30 g/dl (n.v.31-37)




Peripheral blood smear

Differential diagnosis of the most common forms of microcytosis

	Nutritional deficiency	Deficit of absorption	Thalassemia heterozygotes	ACD	ACD+iron deficiency	
Hb	-	-	= / -	-		
MCV	-	-	-	-	-	
GR	-	-	+	-		
RDW	=	=	= / +	= / +	+	
Reticulocytes	-	-	= / +	= / +	= / + / -	
IS	- /	- /	=	= / -	-	
Ferritin	= / -	= / +	=	=	= / -	
FEP	= / +	= / +	=	=	= / +	
sTfR	+	+	+	=	= / +	
CHr	-	-	= / -	-		
Oral response	YES	NO	NO	Not to be expected	Partial	
lv response	YES	YES	NO	Not to be expected	Partial	
Inheritance	Acquired	Acquired / multifactorial	AR	Multifactorial	Multifactorial	
Suggested therapy	Oral iron	Etiological therapy / iv injection if severe anemia	Not required	Etiological therap yif possible (EPO, iv iron)	Etiological therap + oral iron	

Causes of Iron Deficiency Anaemia

- Blood loss
- Limited supply (poor diet)
- Increased requirements
- Iron malabsorption



Unexplained or Refractory Acquired Iron-Deficiency Anaemia (IRIDA)

- Helicobacter pylori
- Celiac disease
- Autoimmune atrophic gastritis

Helicobacter pylori Infection

 In recent years, *H. pylori* has been implicated in several studies as a cause of IDA refractory to oral iron treatment¹

– – Favorable response to *H. pylori* eradication

- Mechanisms: Occult GI bleeding? Alterations in intragastric pH and ascorbic acid concentration? Induction of IL-1β and TNF-α, (inhibitors of parietal cell function)? Induction of parietal cell apoptosis?²
- Diagnosis: IgG antibody screening, urease breath test¹

1. Hershko C, et al. *Semin Hematol.* 2009;46:339-350.

2. Hershko C, et al. Blood Cells Mol Dis. 2007;38:45-53.

Celiac Disease

- Celiac disease is a common nonbleeding gastrointestinal condition that may result in refractory IDA¹
 - Celiac disease accounts for 5%–6% of unexplained IDA cases
 - Approximately 50% of patients with subclinical celiac disease develop IDA
- Diagnosis: Anti-tissue transglutaminase antibodies and/or anti-endomysial antibodies

Hershko C, et al. Semin Hematol. 2009;46:339-350.

Autoimmune Atrophic Gastritis

- Autoimmune atrophic gastritis, or atrophic body gastritis, is associated with chronic idiopathic IDA with no evidence of gastrointestinal blood loss
- Iron deficiency may develop many years before the depletion of vitamin B₁₂ stores
- Possible role of *H. pylori* in the pathogenesis of autoimmune gastritis due to antigenic mimicry of H⁺K⁺-ATPase
- Diagnosis: Serum gastrin, parietal cell antibodies


Hershko C, et al. Semin Hematol. 2009;46:339-350.

Acquired IRIDA

- Blood loss, insufficient dietary iron intake, and increased iron requirements are the main causes of iron deficiency anaemia.
- Acquired decreased iron absorption has recently been recognized in patients with unexplained or refractory IDA
- Celiac disease, autoimmune atrophic gastritis, and *H. pylori* infection are increasingly diagnosed in such patients
- In some cases, *H. pylori* may be directly implicated in the genesis of autoimmune gastritis
- We strongly recommend a diagnostic work-up for these conditions in case of acquired refractory or obscure IDA


Causes of Iron Deficiency Anaemia

- Blood loss
- Limited supply (poor diet)
- Increased requirements
- Iron malabsorption



DMT1 Deficiency

delCTT intron 4 / R416C



Severe microcytic anaemia with high transferrin saturation Severe hypochromia with liver iron overload and normal ferritin levels

	Father, I-1	Mother, I-2			Proband, I	ŀ1				Normal values (range)
Age	35 y	32 y	Birth	2 mo	3 mo	6 mo	1 y	Зу	5 y	2-3 y
Body weight, percentile	NA	NA	< 3rd	Зrd	5th	10th	15th	15th	25th	NA
Hb, g/L	149	128	40	74	76	82	98	90	85	130 (120-150)
MCV, fL	84	79.6	71	75	69	50	50	48	51	80
MCH, pg	28.8	27	14	14	15	15.3	14	13.5	15	26
Serum iron, µM	14.3	12.9	ND	29.7	28.6	30.4	26.5	34.7	36.5	14.3 (10.6-21.5)
Transferrin saturation, %	28	35	ND	85	100	80	63	80	90	7-30
Ferritin, µg/L	110	133	ND	256	864	110	70	26	34	7-140
FEP, μg/g Hb	ND	ND	ND	(4.7)	ND	ND	ND	ND	5.3	< 3
Treatment	None	None	18 mL PRBCs	25 mL PRBCs	30 mL PRBCs	sc rEpo	sc rEpo	sc rEpo	sc rEpo	NA


Graphics A, B, and Table with permission from Iolascon, A. et al. *Blood.* 2006;107:349-354. Top left graphic courtesy of Dr. Achille Iolascon.

The iron cycle

Iron absorption

Enterocyte


- 1–2 mg/day
- Hepcidin-regulated
- Balanced by iron losses (1–2 mg/day)
- Reduced in inflammation
- Increased in iron deficiency



CP = ceruloplasmin; DCYTB = duodenal cytochrome B; DMT1 = divalent metal transporter 1; FPN = ferroportin.

Iron recycling Macrophage

- 20–30 mg/day
- Hepcidin-regulated
- Balanced by erythroid request
- Reduced in inflammation
- Increased in iron deficiency



Finch C. Blood. 1994;84:1697-702. Andrews NC. Blood. 2008;112:219-30.

Clinical and Laboratory Findings of DMT1 Mutations^{1,2}

MCV	45–55 fL	 DMT1 is essential in erythro
Serum iron	+ +	 DMT1 is not essential for live
Tf saturation	+ +	uptake
sTfR	+ +	 DMT1 is not essential for du
BM sideroblasts	_	absorption – Alternative pathways?
FEP	+	– Heme absorption?
Liver iron	+ + +	 Increased iron absorption oc
Neonatal appearance	+	presence of iron overload be low hepcidin levels
Effect oral/IV Fe	-/-	 Partial response of anemia t erythropoietin treatment
Serum or urinary hepcidin	_	
1, Iolascon A, et al. <i>Bl</i> Inheritance Graphic courtesy of D	ood. 2006;107:349-35 r. Achille Iolascon.	4. 2. Iolascon A, et al. <i>J Pediatr.</i> 2008;152:136-139.
Therapy	Еро	


- DMT1 is essential in erythropoiesis
- DMT1 is not essential for liver iron uptake
- DMT1 is not essential for duodenal iron. absorption
 - Alternative pathways?
 - Heme absorption?
- Increased iron absorption occurs in the presence of iron overload because of low hepcidin levels
- Partial response of anemia to erythropoietin treatment

IRIDA = iron refractory-iron deficiency anemia (OMIM #206200)


Autosomal recessive

Caused by inappropriately high hepcidin production

Hepcidin downregulation: multiple pathways



Hepcidin regulation in Iron Deficiency and deregulation in IRIDA



Hematological parameters of the probands

n.	sex	age	Hb	MCV	% TF	Serum	Serum
					saturation	Ft	hepc
А	m	6	8.8	58	2	50	1
В	f	13m	9.2	65	10	37	1
С	m	17m	7.0	49	5	40	1
D	f	11	8.2	56	3		1
E	m	7	7.5	49	4	27	1
F	f	3	9.7	61	4		-
G	m	15m	7.9	53	2	59	1


(Finberg et al, Nature Genetics 2008;40:569-71)

Diseases/condition frequently associated with anaemia and/or ID


- Solid tumours and haematologic malignancies
 - ~40% anaemic, 32-60% iron-deficient
- Chronic kidney disease (CKD)^{4,5}
 - 27-76% anaemic, 58-73% iron-deficient
- Inflammatory bowel disease (IBD)⁶
 - 6-74% anaemic, 36-90% iron-deficient
- Gastrointestinal disorders (GI)^{7,8}
 - 10% (angiodysplasia) to 66% (coeliac disease) anaemic
- Chronic heart failure (CHF)^{9,10}
 - 9-79% anaemic, 43% iron-deficient
- Women's Health conditions¹¹⁻¹³
 - Heavy menstrual bleeding (HMB): 20% anaemic
 - Pregnancy and postpartum: global 42% anaemic, Europe 25% anaemic
 - Non-anaemic, non-pregnant, premenopausal women: 4-33% iron-deficient
- Special populations (elderly, children)^{14,15}
 - Elderly: 3-61% anaemic, Children: 4-7% iron-deficient (US)

- 1. Ludwig. Eur J Cancer 2004;40:2293;
- 2. Aapro. Ann Oncol 2012;23:1954;
- 3. Ludwig. Eur J Cancer 2009 Jun;45(9):1603;
- 4. McClellan. Curr Med Res Opin 2004;20,1501;
- 5. Fishbane. Clin J Am Soc Nephrol 2009;4, 57;
- 6. Kulnigg. Aliment Pharmacol Ther 2006;24,1507;
- 7. Kassam. Can J Gen Intern Med 2009;4:64;
- 8. Unsworth. Lancet 1999;353:1100;
- 9. Silverberg. J Am Coll Cardiol 2000;35:1737;
- 10. Okonko. J Am Coll Cardiol 2011;58:1241;
- 11. Vercellini. J Reprod Med 1993;38:502;
- 12. Bergmann. Geburtsh Frauenheilk 2009;69: 682;
- 13. Hercberg. Public Health Nutr 2001;4:537;
- 14. Beghe. Am J Med 2004:116(7A):3S;
- 15. CDC. MMWR 2002;51;897.

Clinical consequences of anaemia and of ID(A)




Importance of iron for functioning and survival across all levels of complexity of living structures




Jankowska EA, et al. Eur Heart J 2013;34:816-29.

ID is associated with reduced exercise capacity in heart failure (HF) patients



- Iron deficiency defined as serum ferritin <100 μg/L, or serum ferritin 100–300 μg/L with TSAT <20%</p>
- Anaemia defined as haemoglobin level <12 g/dL in women and <13 g/dL in men
- Iron deficiency was present in 35% of patients

ID is associated with reduced exercise capacity in HF patients



Iron deficiency defined as serum ferritin <100 μg/L, or serum ferritin 100–300 μg/L with TSAT <20%</p>

Anaemia defined as haemoglobin level <12 g/dL in women and <13 g/dL in men

Summary and conclusions

- Iron is an essential nutrient
- ID deficiency is prevalent
- ID presents with a broad spectrum of clinical signs and symptoms
- ID has a considerable impact on patients' life
- Diagnosis is based on haematological parameters, which have different cut-off values depending on the disease

Anemia Work up and Differential Diagnosis

